Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by the company's operations in Canada and Latin America.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The repayment underscores the company's financial discipline and ability to generate sufficient cash to meet its obligations while retaining flexibility for future investments.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD.
For more information about the company, please visit Knight Therapeutics. To view the full press release, visit https://ibn.fm/8eluB.
This news matters because it demonstrates Knight Therapeutics' operational strength and financial health, which are critical for sustaining its growth strategy in the competitive pharmaceutical market. The repayment reduces interest expenses and improves the company's balance sheet, potentially enhancing shareholder value. Additionally, maintaining access to the credit facility and accordion feature positions Knight to pursue further acquisitions or investments without immediate financing constraints.
The announcement also highlights the success of the Paladin acquisition, which was completed in June 2025. By repaying the debt within a relatively short period, Knight shows that the acquisition is generating expected returns and cash flows. This could boost investor confidence in management's ability to execute value-creating transactions.
For investors, the repayment signals a lower risk profile and greater financial flexibility. It may also pave the way for increased dividends or share buybacks in the future, as the company allocates its strong cash flow. Overall, the development reinforces Knight Therapeutics' position as a key player in the pan-American pharmaceutical sector.
